Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD525797 · 1 trial · 1 indication
DLT was defined as any Grade 3 or 4 haematological or non-haematological toxicity occurring at any dose level until the end of Week 4, and suspected to be reasonably related to the investigational medicinal product by the Investigator and/or Sponsor. Toxicities not considered to be DLTs are as follows- Allergic reactions or anaphylaxis; any Grade 3 or 4 out-of-range laboratory values without any clinical correlate, which were reversible within 7 days, unless the Investigator decided this event is clinically significant. For this reason Grade 3 or 4 out-of-range laboratory values must be re-assessed within 7 days. In case the Investigator provides the subject any treatment(s) due to the out-of-range laboratory values, the event was regarded as a DLT.
Area under the serum concentration-time curve from time zero to the last sampling time at which the concentration is at or above Lower limit of quantification (LLQ).
Area under the serum concentration-time curve from time zero to the last sampling time at which the concentration is at or above LLQ.
Total body clearance of drug in serum was calculated: as CL= Dose divided by Area under the serum concentration-time curve from time zero to infinity (AUC0-inf).
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of drug in serum was calculated as : CL= Dose/ AUC0-inf. Area under the serum concentration-time curve from time zero to infinity (AUC0-inf), calculated as AUC0-t + AUCextra. AUCextra represents an extrapolated value obtained by Clast / λz, where Clast is the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above LLQ and λz is the elimination rate constant.
Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following single dose. Area under the serum concentration-time curve from time zero to infinity, calculated (AUC0-inf) as AUC0-t + AUCextra. AUCextra represents an extrapolated value obtained by Clast / λz, where Clast is the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above LLQ and λz is the elimination rate constant. And the elimination rate constant obtained from linear regression of the terminal phase of the log transformed concentration-time data. A minimum of three points is required to calculate λz.
The observed serum concentration immediately before next dosing determined directly from the serum concentration-time profile of each subject (= trough concentration).
Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/(Area under the serum concentration-time curve within one complete dosing interval \[AUCtau\]\* λz) following multiple dose.
| Arm | Type | Description |
|---|---|---|
| EMD525797 250 milligram (mg) | EXPERIMENTAL | - |
| EMD525797 500 mg | EXPERIMENTAL | - |
| EMD525797 1000 mg | EXPERIMENTAL | - |
| EMD525797 1500 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EMD525797 | BIOLOGICAL | Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent. |
Inclusion Criteria: * Age greater than or equal to (\>=) 20 years * Histologically or cytologically proven advanced or metastatic solid tumor * Evidence of progressive disease after standard chemotherapy or no standard chemotherapy * Confirmation of availability of formalin-fixed paraffin-embedded ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EMD 525797 is an investigational monoclonal antibody being studied in oncology. It has been evaluated in clinical trials for colorectal and ovarian cancer patients with liver metastases, solid tumors, metastatic colorectal cancer, and prostate cancer with bone metastases. All trials completed Phase 1.
EMD 525797 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential effects in various cancer types, including colorectal, ovarian, and prostate cancer.
EMD 525797 is being developed by Merck KGaA, a German multinational pharmaceutical company. The company's stock is traded over-the-counter under the ticker symbol MKGAF.
EMD 525797 is in Phase 1 clinical development. All four clinical trials listed for the drug are Phase 1 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities.
EMD 525797 has been studied in four completed Phase 1 trials: NCT00848510 in colorectal and ovarian cancer patients with liver metastases, NCT00958477 in prostate cancer with bone metastases, NCT01008475 in combination with cetuximab and irinotecan in K-ras wild type metastatic colorectal cancer, and NCT01327313 in solid tumor patients in Japan.
EMD 525797 is also known as abituzumab, a monoclonal antibody developed by Merck KGaA. The drug has been investigated in Phase 1 trials for various cancers, including colorectal, ovarian, and prostate cancer.